Edronax 4 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

edronax 4 mg tablett

paranova läkemedel ab - reboxetinmesilat - tablett - 4 mg - reboxetinmesilat 5,224 mg aktiv substans

Edronax 4 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

edronax 4 mg tablett

paranova läkemedel ab - reboxetinmesilat - tablett - 4 mg - reboxetinmesilat 5,224 mg aktiv substans

Edronax 4 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

edronax 4 mg tablett

ebb medical ab - reboxetinmesilat - tablett - 4 mg - reboxetinmesilat 5,224 mg aktiv substans

Adempas Europeiska unionen - svenska - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertoni, lungformig - antihypertensiva medel mot pulmonell arteriell hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekt har visats i ett pah befolkning, inklusive aetiologies av idiopatisk eller ärftlig polycykliska aromatiska kolväten eller pah som associeras med bindvävssjukdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Edronax 4 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

edronax 4 mg tablett

pfizer ab - reboxetinmesilat - tablett - 4 mg - reboxetinmesilat 5,224 mg aktiv substans - reboxetin

Maviret Europeiska unionen - svenska - EMA (European Medicines Agency)

maviret

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatit c, kronisk - antivirala medel för systemisk användning - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Kagitz 400 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kagitz 400 mg depottablett

aristo pharma gmbh - kvetiapinfumarat - depottablett - 400 mg - kvetiapinfumarat 460,54 mg aktiv substans; laktosmonohydrat hjälpämne

Kagitz 50 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kagitz 50 mg depottablett

aristo pharma gmbh - kvetiapinfumarat - depottablett - 50 mg - laktosmonohydrat hjälpämne; kvetiapinfumarat 57,568 mg aktiv substans

Kagitz 300 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kagitz 300 mg depottablett

aristo pharma gmbh - kvetiapinfumarat - depottablett - 300 mg - kvetiapinfumarat 345,405 mg aktiv substans; laktosmonohydrat hjälpämne

Mykofenolatmofetil Actavis 250 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mykofenolatmofetil actavis 250 mg kapsel, hård

ebb medical ab - mykofenolatmofetil - kapsel, hård - 250 mg - mykofenolatmofetil 250 mg aktiv substans; propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne